Spike Protein News and Research

RSS

Rapid SARS‐CoV‐2 IgM‐IgG combined antibody test

A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.

15 Oct 2020

Human bivalent SARS-CoV-2 neutralizing antibodies more potent

A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.

15 Oct 2020

Army researchers team up to test alternative ways to measure COVID-19 antibody levels

Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.

14 Oct 2020

Research identifies antigen-specific peripheral T follicular helper cells in COVID-19 infected patients

Researchers have found peripheral T follicular helper cell responses to different structural proteins of SARS-CoV-2 and have studied how the response occurs over time.

14 Oct 2020

Exploring the effects of smoking tobacco on COVID-19 risk

A study conducted by researchers in China has shed light on how certain tobacco compounds might prevent cells from becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

14 Oct 2020

ACE2 binding causes dissociation of trimeric SARS-CoV-2 spike, may be used to inhibit further infection

A recent study published on the preprint server bioRxiv in October 2020 shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding to the human host receptor could cause the typical trimeric spike protein to come apart, forming a stable monomer instead with the receptor.

14 Oct 2020

Study shows SARS-CoV-2 antibodies offer lasting immunity

One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long.

14 Oct 2020

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

A new study published on the preprint server bioRxiv in October 2020 shows that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without the rest of the viral components.

14 Oct 2020

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.

14 Oct 2020

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.

14 Oct 2020

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Researchers at The Medical Research Council Laboratory of Molecular Biology have conducted a study showing how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein interacts with host cell factors in ways that promote the formation of syncytia.

13 Oct 2020

Study offers a better understanding of protective antibodies induced by coronavirus

As vaccine trials progress and public health officials brace for a rise in COVID-19 cases, understanding how the body defends itself from SARS-CoV-2 infection is essential.

13 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses - including several that distinguish it from other COVID-19 vaccine approaches - according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

A new study by Uppsala University researchers published on the preprint server bioRxiv in October 2020 shows possible links between the angiotensin-converting enzyme 2 (ACE2) host cell receptors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the entry of viral particles into the cell via endocytosis and autophagy.

12 Oct 2020

Sub-second heat inactivation of coronavirus

Three coronaviruses (CoVs) have caused global outbreaks within the past 20 years, and with the COVID19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, methods that can rapidly inactivate these viruses can play critical roles in ensuring public safety and safeguarding personal health.

12 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

Spike Protein News and Research

Rapid SARS‐CoV‐2 IgM‐IgG combined antibody test

Human bivalent SARS-CoV-2 neutralizing antibodies more potent

Army researchers team up to test alternative ways to measure COVID-19 antibody levels

Research identifies antigen-specific peripheral T follicular helper cells in COVID-19 infected patients

Exploring the effects of smoking tobacco on COVID-19 risk

ACE2 binding causes dissociation of trimeric SARS-CoV-2 spike, may be used to inhibit further infection

Study shows SARS-CoV-2 antibodies offer lasting immunity

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Study offers a better understanding of protective antibodies induced by coronavirus

COVID-19 vaccine candidate shows potent immune response

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

Sub-second heat inactivation of coronavirus

Nasal spray COVID-19 vaccine shows promising results in mice

COVID-19 survivors may have protective antibodies for 4 months

Temporal predictors of SARS-CoV-2 antibodies

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News